key: cord-1027021-qeu5fvu4
authors: Eberly, Allison R.; Germer, Jeffery J.; Boerger, Aimee C.; Fernholz, Emily C.; Binnicker, Matthew J.; Yao, Joseph D.
title: Performance of Three Polymerase Chain Reaction-Based Assays for Detection of SARS-CoV-2 in Different Upper Respiratory Tract Specimens
date: 2021-05-28
journal: Diagn Microbiol Infect Dis
DOI: 10.1016/j.diagmicrobio.2021.115441
sha: aa585437de3893db33f7abd6952430576cc3e58d
doc_id: 1027021
cord_uid: qeu5fvu4

To meet the testing demands and overcome supply chain issues during the SARS-CoV-2 pandemic, many clinical laboratories validated multiple SARS-CoV-2 molecular testing platforms. Here, we compare three different molecular assays for SARS-CoV-2 that received emergency use authorization (EUA) from the U.S. Food and Drug Administration. In order to determine the agreement among Roche cobas® SARS-CoV-2 Test (Cobas), Abbott RealTime SARS-CoV-2 assay (ART), and Mayo Clinic Laboratory SARS-CoV-2 Molecular Detection Assay (Mayo LDT), 100 each of anterior nares (AN), nasopharyngeal (NP), oropharyngeal (OP), and NP+OP swabs were tested on each platform. The consensus result was defined as agreement by 2 or more methods. Furthermore, 30 positive NP swabs from each molecular platform (n=90 total) were tested on the three platforms to determine the PPA among positive samples. ART platform called more specimens positive than the other two platforms. All three assays performed with greater than 90% agreement for NP specimens throughout the study.

As the global COVID-19 pandemic continues, clinical microbiology laboratories face continued demand for increased testing capacity amidst supply chain issues, forcing clinical laboratories to implement multiple assays for molecular detection of SARS-CoV-2.

Such measures often led to the questions on which tests have the "best" clinical sensitivities and specificities. However, determining the clinical sensitivity and specificity is challenging when there is no gold standard clinical definition of COVID-19.

To determine how test results correlate among the different high-throughput molecular assays and to help guide patient care, we conducted a study to determine the agreement of results obtained on upper respiratory tract specimens tested with 3 molecular assays that have received emergency use authorization (EUA) from the U.S. 

Consecutive upper respiratory tract swab specimens leftover from routine SARS-CoV-2 detection testing at Mayo Clinic Laboratories during April and May of 2020 were used in this study. One hundred consecutive specimens from each of the following sources were obtained from persons under investigation (PUI) for COVID-19, and placed in 3 mL of viral transport media (VTM) or phosphate-buffered saline (PBS): anterior nares (AN), nasopharynx (NP), oropharynx (OP), or combined NP+OP. The combined NP+OP was an NP swab collected first, followed by collection of an OP swab from the same PUI, with both swabs placed in to a 3-mL tube of transport media. For each specimen source, only one specimen submitted for routine testing on each PUI was used in this study, and the four specimen sources are not matched for the study subjects. Due to shortages of assay reagents and consumable supplies, all commercially available brands of VTM, PBS, and saline were acceptable for testing per FDA guidance in deeming them as equivalent (1). All specimens were tested initially with Cobas, stored at 2° -8°C for up to 7 days for testing with the other 2 assays. The consensus result was defined as the result of at least 2 out of 3 testing platforms that was found to be in agreement. Testing with all three assays was performed per manufacturers' instructions for use. For data analysis in this study, indeterminate results generated were grouped in the positive result category, as patients with indeterminate test results are managed clinically as having probable COVID-19.

Specimens with this result type did not have sufficient volume for retesting in this study.

In addition, 30 known-positive NP specimens previously tested with one of the 3 assays (total of 90 specimens) were selected for determination of positive agreement among the 3 assays. These specimens were selected based on target C T values of the initial assay and classified as high-, medium-, or low-positives: C T of <12 high, 12 to 20 medium, and >20 low for ART (37 total cycles); <20 for high, 20 to 30 medium, and >30 low for Cobas (50 total cycles) and Mayo LDT (45 total cycles total), respectively. Although both target C T for each the Cobas and Mayo LDT were within the ranges, only the C T values of the ORF1ab target for Cobas and N target for Mayo LDT were used for data analysis in this study. After testing positive by the initial assay, each of these specimens was tested by the remaining 2 assays.

All three molecular assays used in this study received EUA from the FDA and all are 

Among the 400 total consecutive clinical swab specimens collected from the 4 anatomic sites (AN, NP, OP, NP+OP) and tested with the 3 molecular assays, ART had 100% PPA across all specimen types. Mayo LDT had 100% PPA for AN and NP+OP, while Cobas had 100% PPA for OP and NP+OP. A PPA of <95% was observed for AN and NP with Cobas and for NP and OP with Mayo LDT assay. NPA was >95% across all combinations of assay and specimen type. There were 16 (4%) total discrepancies among results of the 400 specimens (Table S1) 

interpretation. Complicating matters, there is no gold standard diagnosis of COVID-19, and therefore, clinical sensitivity and clinical specificity cannot readily be calculated. Our study supports previous publications showing variability in sensitivity among different specimen types tested on multiple platforms (8, 9) . While other studies highlighted the challenges of utilizing multiple platforms, they did not directly compare the performance between ART and Cobas, let alone comparison to an LDT that is not modified from the original CDC assay.

Our study also compares a relatively large sample size of 4 different specimen types, while several other published studies compared only one specimen type (10) (11) (12) (13) .

Our study has several limitations; all of the 400 prospectively collected clinical specimens were submitted from reference testing laboratory clients without information on the duration of symptoms in the subjects tested. Since the clinical specimens were collected in May 2020 when FDA EUA were granted to assays for testing only PUI, one can only assume that all clinical specimens submitted for testing in our laboratory were collected from PUI. Furthermore, as the 4 specimen types (AN, NP, OP, NP+OP) tested across the 3 different assays in our study did not come from the same 100 subjects, we cannot conclude which specimen type was best for detection of SARS-CoV-2 by each of these 3 assays. Another limitation is that we did not have sufficient volume to retest specimens that had discrepant results. The discrepant results may be explained by several different reasons including extraction, possible contamination, or less sensitive limit of detection (LoD) in the Cobas and/or Mayo LDT assays. The LoD explanation is plausible for 12 out of 16 discrepant results. However, the remaining 4 discrepant results do not appear to be due to the LoD and could be due to the individual assay design of each target.

Additional studies are in progress to evaluate detection rates among matched clinical samples and saliva from individual PUIs, as there is increasing interest in using saliva for noninvasive testing.

Overall, ART, Cobas, and Mayo LDT performed similarly in generating positive or negative results. Our data suggest that ART is the most analytically sensitive of these three assays, and this high sensitivity can likely be attributed to the assay design, in which the same fluorophore is used on both TaqMan probes hybridizing to the viral RdRp and N gene sequences amplified in the assay. In contrast, the Mayo LDT and Cobas use separate fluorophores for the probes targeting different viral target sequences (ORF1ab and E sequences for Cobas and ORF1ab and N sequences for Mayo LDT). Our study data also highlight the finding that not all CT values can be compared across different real-time PCR assays to gauge relative viral load in the same or different clinical specimens obtained from a given individual. As the CT value is dependent on assay design and signal analysis software application, the same specimen tested will likely generate different CT values by different PCR assays. Regression equations, coefficients of determinate (R 2 ), and total number of eligible specimens (N) are shown for each graph. Note that C T values for ART are lower because the signal analysis software was not programmed to count the first 10 amplification cycles. 

Food and Drug Administration. COVID-19 Frequently Asked Questions

Comparison of the analytical sensitivity of seven commonly used commercial SARS-CoV-2 automated molecular assays

Validation and verification of the Abbott RealTime SARS-CoV-2 assay analytical and clinical performance

Abbott RealTime SARS-CoV-2 assay instructions for use

Inc. cobas® SARS-CoV-2: Qualitative assay for use on the cobas 6800/8800 Systems

Evaluation of saline, phosphate buffered saline and minimum essential medium as potential alternatives to viral transport media for SARS-CoV-2 testing

SARS-CoV-2 Molecular Detection Assay EUA summary

Performance of saliva, oropharyngeal swabs, and nasal swabs for SARS-CoV-2 molecular detection: a systematic review and meta-analysis

Comparison of nine different commercially available molecular assays for detection of SARS-CoV-2 RNA

Evaluation of three commercial assays for SARS-CoV-2 molecular detection in upper respiratory tract samples

Clinical evaluation of three sample-to-answer platforms for detection of SARS-CoV-2

Comparison of four molecular in vitro diagnostic assays for the detection of SARS-CoV-2 in nasopharyngeal specimens

Detection of low levels of SARS-CoV-2 RNA from nasopharyngeal swabs using three commercial molecular assays